Clinically relevant concentrations of anticancer drugs: A guide for nonclinical studies

Clinical Cancer Research

Volumn 23, Issue 14, 2017, Pages 3489-3498

  Liston, Dane R ^a   Davis, Myrtle ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; AFATINIB; ALECTINIB; ALFUZOSIN; ALLOPURINOL; ALTRETAMINE; AMIFOSTINE; AMINOGLUTETHIMIDE; AMINOLEVULINIC ACID; ANASTROZOLE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AXITINIB; AZACITIDINE; BELINOSTAT; BENDAMUSTINE; BEXAROTENE; BICALUTAMIDE; BLEOMYCIN; BORTEZOMIB; BOSUTINIB; BUSULFAN; CABAZITAXEL; CABOZANTINIB; CAPECITABINE; CARBOPLATIN; CARFILZOMIB; CARMUSTINE; CERITINIB; UNINDEXED DRUG;

AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; DRUG APPROVAL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDICATION; DRUG LABELING; DRUG PROTEIN BINDING; DRUG RESEARCH; HUMAN; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; DOSE RESPONSE; FOOD AND DRUG ADMINISTRATION; NEOPLASM; ONCOLOGY; TRENDS; UNITED STATES;

ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85024406616     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-3083     Document Type: Review

References (30)

1. Smith MA, Houghton P. A proposal regarding reporting of in vitro testing results. Clin Cancer Res 2013;19:2828–33.
2. National Cancer Institute. A to Z list of cancer drugs. Available from: https://www.cancer.gov/about-cancer/treatment/drugs.
3. MediLexicon. FDA approved drugs» cancer & oncology. Avaialble from: http://www.medilexicon.com/drugs-list/cancer.php.
4. Centerwatch. FDA approved drugs for oncology. Available from: http://www.centerwatch.com/drug-information/fda-approved-drugs/therapeutic-area/12/oncology.
5. U.S. Food and Drug Administration. Drugs@FDA: FDA approved drug products. Available from: http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
6. National Library of Medicine DailyMed. DailyMed. Available from: https://dailymed.nlm.nih.gov/dailymed/index.cfm.
7. Thompson-Reuters PS. Integrity®. Available from: https://integrity.thomson-pharma.com/integrity/xmlxsl/pk_self_reg.show_initial_page.
8. U.S. Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations. Avaialble from: http://www.accessdata.fda.gov/scripts/cder/ob/.
9. Reid JM, Kuffel MJ, Miller JK, Rios R, Ames MM. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res 1999;5:2192–7.
10. Peterson JK, Houghton PJ. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 2004;40:837–44.
11. Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6:2012–21.
12. Haznedar JO, Patyna S, Bello CL, Peng GW, Speed W, Yu X, et al. Single- and multiple-dose disposition kinetics of sunitinib malate, a multi-targeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemother Pharmacol 2009;64: 691–706.
13. Yamazaki S, Skaptason J, Romero D, Vekich S, Jones HM, Tan W, et al. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model. Drug Metab Dispos 2011;39:383–93.
14. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008;22:659–61.
15. Tang H, Mayersohn M. A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Dispos 2005;33:1297–303.
16. Obach RS. Predicting clearance in humans from in vitro data. Curr Top Med Chem 2011;11:334–9.
17. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997;283: 46–58.
18. Hoshino-Yoshino A, Kato M, Nakano K, Ishigai M, Kudo T, Ito K. Bridging from preclinical to clinical studies for tyrosine kinase inhibitors based on pharmacokinetics/pharmacodynamics and toxicokinetics/ toxicodynamics. Drug Metab Pharmacokinet 2011;26:612–20.
19. Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, et al. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 2009;49:513–33.
20. Mathijssen RH, de Jong FA, Loos WJ, van der Bol JM, Verweij J, Sparreboom A. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? Oncologist 2007;12:913–23.
21. Spilker ME, Chen X, Visswanathan R, Vage C, Yamazaki S, Li G, et al. Found in translation: maximizing the clinical relevance of nonclinical oncology studies. Clin Cancer Res 2017;23:1080–90.
22. Singh J, Petter RC, Baillie TA, Whitty A. The resurgence of covalent drugs. Nat Rev Drug Discov 2011;10:307–17.
23. Giannetti AM, Wong H, Dijkgraaf GJ, Dueber EC, Ortwine DF, Bravo BJ, et al. Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449). J Med Chem 2011;54: 2592–601.
24. Jordan VC, Collins MM, Rowsby L, Prestwich G. A monohydrxylated metabolite of tamoxifen with potent antiestrogenic activity. J Endocr 1977; 75:305–16.
25. Jordan VC, Bain RR, Brown RR, Gosden B, Santos MA. Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. Cancer Res 1983; 43:1446–50.
26. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30–9.
27. Dickschen K, Willmann S, Thelen K, Lippert J, Hempel G, Eissing T. Physiologically based pharmacokinetic modeling of tamoxifen and its metabolites in women of different CYP2D6 phenotypes provides new insight into the tamoxifen mass balance. Front Pharmacol 2012;3:92.
28. Robinson SP, Langan-Fahey SM, Jordan VC. Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. Eu J Cancer Clin Oncol 1989;25:1769–76.
29. Lukas G, Brindle SD, Greengard P. The route of absorption of intraperitoneally administered compounds. J Pharmacol Exp Ther 1971; 178:562–6.
30. Lu Z, Wang J, Wientjes MG, Au JL-S. Intraperitoneal therapy for peritoneal cancer. Fut Oncol 2010;6:1625–41.